Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema (MODEVA)
Aflibercept Injection for Treatment of Diabetic Macular Edema
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- Dr DOMINGUEZ
-
Lyon, France, 69004
- Pr KODJIKIAN
-
Nantes, France, 44300
- Dr Franck BECQUET
-
Rouen, France, 76100
- Dr UZZAN
-
-
Hauts De France
-
Amiens, Hauts De France, France, 80000
- Pr MILAZZO Solange
-
Lomme, Hauts De France, France, 59160
- Tran Thi Ha Chau
-
-
Ile De France
-
Paris, Ile De France, France, 75010
- Bénédicte DUPAS
-
-
Paca
-
Nice, Paca, France, 06001
- Stéphanie BAILLIF
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diabetic patients aged between 19 and 90 years old
- Patients with the following characteristics at the beginning of the Aflibercept therapy :
HbA1c < 9% Diabetic macular oedema with the central affected Visual acuity between 1/20 and 5/40 (between 20 and 70 letters ETRS) Patients who had a vitrectomy over 3 months ago
- Patients who did not received an anti-VEGF treatment or any other treatment for their diabetic macular edema 3 months before the beginning of the injections
Exclusion Criteria:
- Patients who refused the collection of their data in medical records
- Patients with a macular ischemia of more than 1500µm diagnosed via an avascular central fluorescein angiography before the inclusion
- Patients with a recent cardiovascular incident (heart attack, stroke dating for less than 3 months before the inclusion)
- Pregnancy at the moment of inclusion
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimation of visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS)
Time Frame: 96 weeks
|
Estimation of visual acuity after 96 weeks of treatment with Aflibercept
|
96 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure of the central macular thickness
Time Frame: 96 weeks
|
Describe the evolution of the Central macular thickness during treatment
|
96 weeks
|
|
Quantification of number of Aflibercept injections received
Time Frame: 96 weeks
|
96 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thi Ha Chau TRAN, PhD, Groupement des Hôpitaux de l'Institut Catholique de Lille
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RC-P0051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.